BDRX$2.78-0.71%
Biodexa Pharmaceuticals Plc
Sector: Pharmaceutical PreparationsIndustry: BiotechnologyCountry: GBExchange: Nasdaq
Mkt Cap:$2.86M
Float & O/S:
Inst Own:
DilutionScan read 47 of Biodexa Pharmaceuticals Plc's SEC filings and found 22 warrant series, 1 equity line, 2 shelf registrations, 8 S-1 registrations and 4 completed offerings on file for BDRX. The latest dilution event on file is a registration statement on Sep 30, 2026. Analysis updated Oct 26, 2026.
Signal8 Summary
BDRX
Going-concern warning, fresh reverse split
Snapshot
Biodexa is a clinical-stage biotech with no meaningful revenue, a $8.4M net loss in FY 2025, and cash of $11.5M against a burn rate that leaves only about 14 months of runway.
What's Happening Right Now
- : A filing registers resale of shares tied to warrants from a July 2026 raise, described as a significant overhang versus the public float, and cites a going-concern warning from auditors.
- : Biodexa passed the halfway point in recruitment for its Phase 3 Serenta trial in familial adenomatous polyposis, with 87 of 168 planned subjects enrolled.
- : Shareholders approved a drastic 1-for-10,000 reverse split effective July 30, 2026, undertaken to satisfy Nasdaq's minimum bid price requirement.
- : A $3.5 million financing priced shares at a steep discount to net tangible book value, expected to cut per-share book value by more than half.
- : Health Canada approved expansion of the Serenta Phase 3 trial into Canada, adding to the 29 active recruiting sites across the US and Europe.
